General
Preferred name
GUANIDINE
Synonyms
GUANIDINE CARBONATE ()
GUANIDINE HYDROCHLORIDE ()
Guanidine HCl ()
Aminoformamidine HCl ()
Aminoformamidine Hydrochloride ()
Guanidinium chloride ()
Guanidine (hydrochloride) ()
Guanidine thiocyanate ()
Guanidinium (chloride) ()
Aminoformamidine (hydrochloride) ()
NSC-755884 ()
P&D ID
PD009973
CAS
593-85-1
50-01-1
124-46-9
106946-18-3
113-00-8
593-84-0
109028-07-1
Tags
available
drug
Approved by
FDA
First approval
1939
Drug indication
neuroendocrine neoplasm
Muscle fatigue
Myasthenic syndrome
Myasthenia gravis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Guanidine hydrochloride (Guanidinium chloride) a strong chaotrope, is also a strong denaturant of proteins[1][2].
PRICE
29
DESCRIPTION
Guanidine is the functional group on the side chain of arginine (). It is a normal product of protein metabolism and is excreted by the kidney.
(GtoPdb)
PRICE
208
DESCRIPTION
Guanidine is a strong chaotropic agent and a strong denaturant of proteins.
DESCRIPTION
Guanidine thiocyanate is a strong protein denaturant and potent inhibitor of nucleases. Guanidinium thiocyanate is a nucleic acid protector in the extraction of DNA and RNA from cells. Guanidine thiocyanate is a common component of buffers used for nucleic acid extraction[1].
DESCRIPTION
Guanidine is used to treat muscle weakness and fatigue associated with the myasthenic complications of Eaton-Lambert syndrome.
(Enamine Bioactive Compounds)
DESCRIPTION
Guanidine hydrochloride (Aminoformamidine Hydrochloride) is a strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
23
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
JUMP-Target 1 Compound Set
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
151
Molecular Weight
59.05
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
3
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
-1.16
TPSA
75.89
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.24
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
ALDH2, DLG4, GAMT, RNASE1
RNASE1
Endogenous Metabolite
Arginase
Argininosuccinate synthase
Lysozyme
Ribonuclease pancreatic
Indication
Lambert-Eaton myasthenic syndrome (LEMS)
MOA
HSP inhibitor
Pathway
Autophagy
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Immunology/Inflammation
Metabolism
Metabolic Enzyme/Protease
Therapeutic Class
Neurology Agents
Source data

